Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions.
Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early.
Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body.
This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites.Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines.The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis.
The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding.According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program.Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Can you take antibiotics for COVID? WHO updates its guidelines on antibiotic usage for patients
As COVID-19 continues to evolve, so do the guidelines for how to tackle and treat it. Although the pandemic has drawn to a close, various strains are still at play and are causing infection amongst communities. After the Nimbus strain, now the Stratus strain is surging in the US, causing soar throat and hoarseness in voice in patients. Although these strains aren't fatal, many people still wonder: Can you take antibiotics for COVID? The answer, finally, is here. The latest guideline In a major update to its clinical guidelines, the World Health Organization (WHO) has advised against giving antibiotics to COVID-19 patients, even those with severe illness, if there's no clear sign of a bacterial infection. This shift in guidance comes after a new meta-analysis of studies showed that antibiotics do not improve outcomes in COVID-19 patients who don't have a bacterial infection. Overusing antibiotics without need, the WHO warns, could worsen the global problem of antimicrobial resistance. 'For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics,' the WHO said in its latest guidance. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kate Middleton's Daring Outfit Took Prince William's Breath Away Crowdy Fan Undo 'For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics.' What are antibiotics? Antibiotics are medicines used to treat bacterial infections, not viral infections like COVID-19. They work by killing bacteria or stopping them from growing. Common illnesses treated with antibiotics include strep throat, urinary tract infections, and some types of pneumonia. COVID-19, however, is caused by the SARS-CoV-2 virus, not a bacterium. This means antibiotics do not treat the virus itself. Taking them unnecessarily won't help you recover faster, and it can cause serious side effects or even long-term health problems. Why the change? Since the beginning of the pandemic in 2020, both COVID-19 and the world's response to it have changed dramatically, the WHO noted. With lower infection rates, milder disease, and the removal of emergency public health measures, COVID-19 is now treated more like other illnesses in many countries. 'Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity,' the WHO said. 'Care for patients with COVID-19 has become more integrated with usual healthcare systems.' These changes prompted the WHO to review and revise all of its existing COVID-related recommendations. As a result, the new guidelines remove outdated advice or recommendations that are now considered basic medical practice and not specific to COVID-19. Recommendation backed by new research The updated antibiotic recommendations are based on the latest data from a systematic review and meta-analysis. These studies looked at how patients fared when treated with antibiotics during COVID-19, and whether those treatments were really necessary in the absence of a bacterial infection. At the same time, there's growing urgency to tackle antimicrobial resistance, a serious global threat where overuse of antibiotics makes bacteria resistant to treatment. The WHO stressed that these new guidelines are aimed at everyone involved in COVID-19 care, from doctors and nurses to hospital administrators and health system planners. COVID-19: Still a threat, and ever-evolving While vaccines, treatments, and previous infections have helped many people build immunity, COVID-19 hasn't disappeared. The SARS-CoV-2 virus continues to infect thousands of people daily, causing avoidable sickness and death. 'The virus continues to evolve in terms of infectivity, immune escape, and disease severity,' the WHO warned. Even though many countries are no longer in emergency mode, COVID-19 still requires careful clinical management, especially for high-risk populations. The new WHO guideline aims to reflect this shifting landscape, balancing new scientific evidence with the current global health context. 'This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19,' the WHO added. To sum it up… Antibiotics should not be used in COVID-19 patients unless there is a strong suspicion of a bacterial infection. This applies to both mild and severe cases. The guidance is part of a broader update reflecting new evidence and a changing pandemic. Overuse of antibiotics can worsen antimicrobial resistance, a growing health threat worldwide. The new guidelines apply to all levels of the health system involved in COVID-19 care. Study finds antiseptic drug is as good as antibiotics for preventing recurrent Urinary Tract Infections
Hindustan Times
6 hours ago
- Hindustan Times
Lok Nayak Hospital ex-director booked by CBI for irregularities
The Central Bureau of Investigation (CBI) has registered a case against Dr Suresh Kumar, former medical director of Delhi government-run Lok Nayak Hospital (LNH), and others for alleged criminal conspiracy, breach of trust, and misconduct by a public servant, officials said on Monday. The case pertains to alleged irregularities in a 2017 open tender floated by LNH on the Delhi government's procurement portal for sanitation consumables and non-consumables. (File photo) The FIR, filed on July 30, comes three years after a preliminary enquiry (PE) was initiated by the CBI in 2022 following reports of administrative lapses during Dr Kumar's tenure. According to officials, the PE has now led to the registration of a regular case (RC) after prima facie evidence was found. 'Prima facie offences under IPC Section 120-B read with Section 409 and Section 13(2) read with Section 13(1)(a) of the Prevention of Corruption Act have been disclosed against Dr Suresh Kumar and other former staff,' the FIR stated. HT has accessed a copy of the document. The case pertains to alleged irregularities in a 2017 open tender floated by LNH on the Delhi government's procurement portal for sanitation consumables and non-consumables, including macerators — machines used for hygienically disposing of human waste. The FIR alleges that only one firm was favoured repeatedly over an extended period, from the original contract period in 2017 until 2021, leading to 'undue benefits' to the firm and corresponding losses to the government. Eight macerators of 'inferior quality' were allegedly purchased at inflated prices, despite better-quality alternatives being available at lower costs. 'No fresh open tender was floated during the extended period,' the FIR adds, 'and extensions were granted to the same firm without justification -- from January 29, 2020, to July 13, 2021.' It also notes that the Covid-19 pandemic, often cited for emergency procurement, only began affecting India in mid-March 2020 -- two months after the original tender expired. The PE further flagged violations in medicine procurement norms. Under government policy, generic medicines -- which are more affordable and equally effective -- are to be prioritised over branded drugs. However, the FIR alleges that between April 7 and September 16, 2022, LNH procured medicines worth ₹32.23 crore from a local authorised chemist, of which ₹25.17 crore (approximately 80%) was spent on branded drugs, and only ₹7.05 crore on generic ones. 'This resulted in avoidable expenditure and reduced access to essential medicines for the public,' the FIR states. CBI officials said CCTV footage, procurement records, and other evidence are being examined to identify the officials involved in the decision-making process. So far, no arrest has been made in the case. Dr Kumar has not responded to messages and calls requesting comment on the matter till the time of going to print.
Time of India
12 hours ago
- Time of India
28 ventilators lie idle in Hazaribag hosp since 2020, superintendent assures action
1 2 Hazaribag: Since the height of the Covid-19 in 2020, 28 life-saving ventilators have been gathering dust in the ICU of Sheikh Bhikhari Medical College Hospital, unused and forgotten, Hazaribag's Sadar MLA, Pradip Prasad, has raised alarm over this critical healthcare oversight at the health unit. These machines, purchased to combat the pandemic, have yet to see the light of day, leaving patients in dire need to be referred to Ranchi for critical care. Prasad has called this not just negligence but a dangerous gamble with the lives of those seeking medical help. He has demanded swift action from the state health department to rectify this oversight immediately. Speaking to TOI, Prasad said, "These ventilators have been sitting idle for years. No steps were taken to operationalise them, nor was there any effort to appoint trained operators. This is a grave disservice to our community." Prasad also highlighted shone a light on other pressing issues plaguing the hospital, including cleanliness, a shortage of medicines, poorly maintained equipment, and a lack of staff. He stressed the urgent need for solutions. In response to Prasad's concerns, his team met with the hospital superintendent, Dr Anukaran Purti, to delve into these issues. They discussed the hospital's current system, resource status, and the challenges faced on the ground. Purti, acknowledging the gravity of the situation, promised swift action. "I will address these issues, including the ventilators, to ensure they are operational soon," he said.
